Search research articles
Contact Us
Filters
Showing results (51-60 of 216) with videos related to
Page
of 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2019
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers-Response
Anu Sharma, Sumit K Subudhi, Jorge Blando, et al.
Cancer Cell
|
March 15, 2022
A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events
Sangeeta Goswami, Bilal A Siddiqui, Sumit K Subudhi, et al.
The Journal of Experimental Medicine
|
March 22, 2024
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype
Naveen Sharma, Xiaozhou Fan, Oluwatomisin T Atolagbe, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 27, 2008
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
Chrysoula I Liakou, Ashish Kamat, Derek Ng Tang, et al.
The Journal of Urology
|
November 17, 2009
Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model
Surena F Matin, Padmanee Sharma, Inderbir S Gill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2006
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma
Padmanee Sharma, Yu Shen, Sijin Wen, et al.
Cancer Immunology Research
|
April 30, 2014
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy
Derek Ng Tang, Yu Shen, Jingjing Sun, et al.
European Urology Oncology
|
November 12, 2020
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder
Mathieu Rouanne, Dean F Bajorin, Raquibul Hannan, et al.
Science Advances
|
September 10, 2025
Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy
Jielin Liu, Shelley Herbrich, Sreyashi Basu, et al.
Cancer Discovery
|
April 3, 2021
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A Siddiqui, Swetha Anandhan, et al.
Page
of 22
Search research articles
Search
Showing results (51-60 of 216) with videos related to
Sort By:
Page
of 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2019
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers-Response
Anu Sharma, Sumit K Subudhi, Jorge Blando, et al.
Cancer Cell
|
March 15, 2022
A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events
Sangeeta Goswami, Bilal A Siddiqui, Sumit K Subudhi, et al.
The Journal of Experimental Medicine
|
March 22, 2024
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype
Naveen Sharma, Xiaozhou Fan, Oluwatomisin T Atolagbe, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 27, 2008
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
Chrysoula I Liakou, Ashish Kamat, Derek Ng Tang, et al.
The Journal of Urology
|
November 17, 2009
Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model
Surena F Matin, Padmanee Sharma, Inderbir S Gill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2006
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma
Padmanee Sharma, Yu Shen, Sijin Wen, et al.
Cancer Immunology Research
|
April 30, 2014
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy
Derek Ng Tang, Yu Shen, Jingjing Sun, et al.
European Urology Oncology
|
November 12, 2020
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder
Mathieu Rouanne, Dean F Bajorin, Raquibul Hannan, et al.
Science Advances
|
September 10, 2025
Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy
Jielin Liu, Shelley Herbrich, Sreyashi Basu, et al.
Cancer Discovery
|
April 3, 2021
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A Siddiqui, Swetha Anandhan, et al.
Page
of 22